Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.


Christoph Bieri, Chair of IMAP’s Healthcare Industry Group, was invited to present at CPhi in Madrid this month, sharing IMAP’s insights into Pharma industry M&A drivers.

The event saw senior representatives and key stakeholders from all segments of the industry meeting to discuss evolving industry trends and hear exclusive views directly from important industry players.

Bieri began explaining why IMAP is in agreement with most industry observers that Pharma M&A is in an overheated Phase which will likely abate soon.  However, as he elaborated, health system cost pressures on the industry are increasing and R&D costs have become prohibitively high.  Thus IMAP anticipates a further streamlining and reorganization of the industry over the next decade, mainly through continuing M&A.

Bieri’s insights were unanimously well received. IMAP’s innovative “4 Strategic Archetypes Model” proved especially thought provoking to members of the audience and industry press alike. The model predicts that Pharma companies will be forced to choose between one of four strategies: Originators, generics (later biosimilars), point-of-call specialists and OTC marketers.  It assumes that each archetype requires a distinct set of skills, culture and strengths, which to some extent are mutually exclusive.  With many Pharma companies today still mixing archetypes, focusing on just one will be the fundamental M&A driver.

Turning to the implications for Pharma manufacturing, Bieri pointed out that Pharma companies, with the notable exception of generic drug providers, are realizing that in-house manufacturing is not a core competence.  Outsourcing and in particular divestments of manufacturing units, combined with service contracts to buyer/operators are increasing.

Christoph Bieri, IMAP Healthcare Industry Group Chair summarized “Whereas in the past, Pharma was fully integrated and worked with many small CMOs, in the future we will see vertically disintegrated Pharma companies working with a tiered supply chain, following in the steps of the automotive industry”.

The full presentation is available by contacting Claire Smedley at IMAP.

Established in 1973 and present in more than 40 countries, IMAP consistently ranks amongst the top M&A mid-market advisors worldwide.  With over 200 deals completed in 2014, IMAP’s sector expertise, dedicated professionals and cross-border collaboration continue to drive its differential value proposition globally. More information can be found at www.imap.com